AC
REGN icon

Arjuna Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Arjuna Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-457
Closed -$353K – 119
2026
Q1 		$353K Buy
457
+14
+3% +$10.7K 0.09% 99
2025
Q4 		$342K Buy
+443
New +$301K 0.08% 97
2024
Q4 		– Sell
-282
Closed -$296K – 110
2024
Q3 		$296K Buy
282
+1
+0.4% +$1.11K 0.08% 91
2024
Q2 		$295K Buy
281
+2
+0.7% +$1.94K 0.08% 92
2024
Q1 		$269K Buy
279
+18
+7% +$17.1K 0.08% 94
2023
Q4 		$229K Buy
+261
New +$215K 0.07% 89
2023
Q3 		– Sell
-1,621
Closed -$1.16M – 102
2023
Q2 		$1.16M Buy
1,621
+81
+5% +$62.5K 0.41% 65
2023
Q1 		$1.27M Buy
1,540
+281
+22% +$212K 0.5% 57
2022
Q4 		$908K Buy
+1,259
New +$929K 0.42% 62

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Arjuna Capital's REGN Position: Q2 2026 in Review

Arjuna Capital sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 457 shares — an estimated $353K sold.

Arjuna Capital first reported a position in REGN in Q4 2022 and held it in 9 quarters. The position peaked at $1.27M in Q1 2023. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Arjuna Capital reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Arjuna Capital sold 457 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $353K.
  • Arjuna Capital first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 9 quarters.
  • Arjuna Capital's Regeneron Pharmaceuticals position peaked at $1.27M in Q1 2023.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Arjuna Capital's 13F filing for Q2 2026, filed 14 Aug 2026.